Arcus Biosciences (RCUS) Earnings Date & Reports

Key Takeaways

• Net loss narrowed to $128 million, or $(1.00) per share, from $135 million, or $(1.27) per share, in the same quarter a year earlier.
• Total revenue fell 65.4% year over year to $9 million, reflecting the wind-down of activities under the Gilead collaboration.
• Research and development (R&D) expenses declined to $117 million from $141 million, driven by streamlining initiatives and the conclusion of domvanalimab-related studies.
• Arcus updated its full-year 2026 GAAP revenue guidance to a range of $70 million to $75 million.
• For additional detail on Arcus Biosciences' Major News, Today's Price Move, Price Targets, and Forecast, explore our dedicated pages.
• Discover new trading ideas with Trending AI Robots.

Earnings Context and Why It Matters

Arcus Biosciences is a clinical-stage biopharmaceutical company advancing oncology and immunology programs, and its quarterly results offer investors a window into both spending discipline and pipeline progress. The third quarter of 2026 marked a transitional period as the company wound down late-stage studies for domvanalimab while redirecting resources toward casdatifan, its HIF-2α (hypoxia-inducible factor 2-alpha) inhibitor for kidney cancer. With revenue tied to collaboration milestones that fluctuate widely from quarter to quarter, the report's most meaningful signals come from cost trends, cash runway, and clinical execution rather than top-line figures.

Reported Results

Arcus reported total revenue of $9 million for the third quarter of 2026, down 65.4% from $26 million in the prior-year period. The decline primarily reflected lower revenue from activities under the Gilead collaboration as those programs wind down or reach completion.

Net loss narrowed to $128 million, or $(1.00) per share (basic and diluted), compared with $135 million, or $(1.27) per share, a year earlier. The loss per share came in modestly wider than the consensus estimate of roughly $(0.89).

Operating expenses continued to trend lower. Research and development (R&D) expenses declined to $117 million from $141 million, while general and administrative (G&A) expenses fell to $23 million from $27 million, reflecting the company's streamlining efforts. Arcus also updated its full-year 2026 GAAP (Generally Accepted Accounting Principles) revenue guidance to a range of $70 million to $75 million.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to streamline your research and uncover new opportunities aligned with your strategy.

Market Reaction and Investor Sentiment

Heading into the report, analyst estimates had pointed to a net loss of roughly $(0.89) per share on approximately $8 million in revenue. The reported $(1.00) loss per share came in slightly wider than that consensus, while revenue of $9 million was broadly in line with or modestly above some estimates. For a development-stage biotechnology company, however, investors tend to weigh pipeline updates and cash position more heavily than quarterly per-share figures, and the narrowing loss alongside declining operating expenses was generally viewed as consistent with the company's cost-discipline strategy.

Forward Outlook and Key Factors to Monitor

Looking ahead, several factors will shape how investors assess Arcus Biosciences. The company reported cash, cash equivalents, and marketable securities of $694 million as of September 30, 2026, down from roughly $1.0 billion at the end of 2025, and noted that a $288 million October equity financing extends its runway to fund planned operations into 2029.

The most important catalyst remains clinical data for casdatifan, the lead HIF-2α inhibitor being evaluated in clear cell renal cell carcinoma. Additional readouts across the pipeline, including the CD73 (an enzyme involved in tumor immune evasion) inhibitor quemliclustat, will also be closely watched.

Investors should monitor whether R&D expenses remain controlled even as spending shifts toward casdatifan, the pace of enrollment in registrational studies, and any updates to collaboration revenue as legacy programs conclude. These dynamics will be central to evaluating both the balance sheet and the long-term clinical value of the portfolio.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations